The Consensus Definition of Bronchopulmonary Dysplasia Is an Adequate Predictor of Lung Function at Preschool Age

Segundo Rite [1,2]*, Carlos Martín de Vicente [3], Juan P. García-Iñiguez [3], María L. Couce [4,5,6], María P. Samper [2], Alicia Montaner [7] and Carmen Ruiz de la Cuesta [2]

[1] Division of Neonatology, Department of Pediatrics, Miguel Servet University Hospital, Zaragoza, Spain, [2] Department of Microbiology, Pediatrics, Radiology and Public Health, University of Zaragoza, Zaragoza, Spain, [3] Division of Neumology, Department of Pediatrics, Miguel Servet University Hospital, Zaragoza, Spain, [4] Division of Neonatology, University Clinical Hospital of Santiago, Santiago de Compostela, Spain, [5] Department of Forensic Sciences, Pathology, Gynecology and Obstetrics, and Pediatrics, University of Santiago de Compostela, Santiago de Compostela, Spain, [6] Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain, [7] Division of Neonatology, Vall d'Hebron University Hospital, Barcelona, Spain

Background: Recent attempts to refine the definition bronchopulmonary dysplasia (BPD) have based its predictive capacity on respiratory outcome in the first 2 years of life, eliminating the pre-existing requirement of 28 days of oxygen therapy prior to 36 weeks postmenstrual age (PMA). The objective of this study was to assess the utility of the 2001 consensus definition in predicting impaired lung function at preschool age.

Methods: This cohort study included children aged 4–6 years old who were born at gestational age (GA) <32 weeks or bodyweight <1500 g. Univariate and multivariate analyses were performed to assess differences in antenatal and neonatal variables between BPD and non-BPD children. All participants underwent incentive spirometry. Lung function parameters were contrasted with the Global Lung Function Initiative (GLI-2012) reference equations and, together with antenatal and neonatal variables, compared among the different subgroups (no BPD, mild BPD, and moderate-to-severe BPD). A multivariate model was generated to identify independent risk factors for impaired lung function.

Results: GA, hemodynamically significant patent ductus arteriosus, and late sepsis were independent risk factors for the development of BPD. A total of 119 children underwent incentive spirometry. All lung function parameters were significantly altered relative to reference values. Greater impairment of lung function was observed in the mild BPD vs. the no BPD group (forced expiratory volume in the first 0.75 seconds [$FEV_{0.75}$]: -1.18 ± 0.80 vs. -0.55 ± 1.13; $p = 0.010$), but no difference in forced vital capacity (FVC) was observed (-0.32 ± 0.90 vs. -0.18 ± 1; $p = 0.534$). The moderate-to-severe BPD group exhibited the most severe $FEV_{0.75}$ reduction ($FEV_{0.75}$: -2.63 ± 1.18 vs. -0.72 ± 1.08; $p = 0.000$) and was the only condition with FVC impairment (FVC: -1.82 ± 1.12 vs. -0.22 ± 0.87; $p = 0.000$). The multivariate analysis identified a diagnosis of moderate-to-severe BPD as an independent risk factor for lung function impairment.

Conclusion: The 2001 consensus definition of BPD has adequate predictive capacity for lung function measured by spirometry at 4–6 years of age. Moderate-to-severe BPD was the best predictor of respiratory impairment. Children with mild BPD showed greater alteration of $FEV_{0.75}$ than those without BPD.

Keywords: bronchopulmonary dysplasia, lung function, preterm infant, spirometry, preschool age

INTRODUCTION

In recent years there has been a significant decrease in mortality and morbidity among the most immature preterm infants. Bronchopulmonary dysplasia (BPD) is a chronic lung disease caused by multiple factors, including immaturity of the airway, that results in impaired lung growth, affecting both the airway and the pulmonary vessels [1]. According to some reports, the incidence of this disease is not decreasing, but rather showing an upward trend [2]. This condition is one of the most common sequelae of prematurity, and can lead to impairment of respiratory function that persists for life.

Since first described by Northway in 1967 [3], the diagnostic definition of BPD has undergone several changes [4, 5]. Shennan's contribution [6] was the first that sought to predict death and respiratory morbidity in the first 2 years of life. The National Institute of Health (NIH) consensus definition, proposed in 2001, specified the requirement of supplemental oxygen for at least 28 days, and categorized BPD as mild, moderate, or severe at 36 weeks postmenstrual age (PMA) [7]. Despite the consensus, debate arose over the following years about several aspects of the definition, including new modes of respiratory support (e.g., high-flow nasal cannulas) and potentially sub-optimal stratification according to disease severity [8]. A recent workshop conducted at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) proposed further modifying the definition of BPD by incorporating the requirement of specific supplemental oxygen with oxygen saturation targeting, along with the mode of respiratory support and radiographic changes at 36 weeks PMA [9]. However, the latter proposal, as well as that of Jensen et al. [10] based on their evidence-based approach, leave certain issues unresolved, especially because the Jensen study considers respiratory morbidity as a primary outcome exclusively during the first 2 years of life and does not consider long-term lung function outcomes.

In the present study we sought to evaluate the utility of the NIH consensus definition of BPD in predicting lung function compromise in preschool age children who underwent incentive spirometry.

METHODS

Patients

This prospective study analyzed retrospectively collected data pertaining to a cohort of infants who were born between 2008 and 2011 in a level III hospital with a birth weight <1500 g and gestational age (GA) <32 weeks, and were identified in the neonatal follow-up unit between 2015 and 2016.

All children aged 4–6 years without congenital abnormalities or major neurological involvement were eligible to participate in the study. Exclusion criteria were as follows: severe cognitive impairment, cerebral palsy, history of post-haemorrhagic hydrocephalus, periventricular leukomalacia or additional comorbidity which may contribute to respiratory morbidity such as severe gastroesophageal reflux, etc. Episodic wheezing, acute viral bronchiolitis, and asthma were not considered criteria for exclusion.

Participants were seen by a pediatrician for physical examination, a respiratory questionnaire was completed by their parents, and a lung function test was conducted.

Outcome Variables and Definitions
### Antenatal and Neonatal Variables

Single or multiple gestation; premature rupture of membranes >18 h; clinical chorioamnionitis [11] (defined as the presence of uterine tenderness and/or purulent or foul-smelling amniotic fluid with any two of the following: antepartum temperature of 37.8°C or more, maternal tachycardia >120 beats/min, maternal leukocytosis >18,000 cells/mm³, or fetal tachycardia >160 beats/min); hypertensive disease of pregnancy; antenatal steroids; intrauterine growth restriction [12]; sex; GA; birth weight; mode of delivery; clinical risk index for babies (CRIB) score [13]; intubation in delivery room; mechanical ventilation modalities; need for invasive ventilation at 7 days of age; duration of invasive ventilation; need for inotropic support in first week of life; hemodynamically significant patent ductus arteriosus (PDA); need for surgical closure of PDA; late sepsis; BPD defined according to the NIH consensus definition [7] [supplemental oxygen required for at least 28 days, defined as *mild* [breathing room air at 36 weeks PMA or discharge], *moderate* (need for <30% oxygen at 36 weeks PMA or discharge), or *severe* (need for ≥30% oxygen and/or positive pressure at 36 weeks PMA or discharge)]. Cases of moderate and severe BPD were combined for the purpose of statistical analysis.

Respiratory Data Up to 4–6 Years of Age

Family history of allergy or asthma, parental smoking; history of atopic dermatitis and recurrent wheezing (three or more episodes in 6 months). At the time of the study, the presence of persistent recurrent wheezing was recorded.

Lung Function Parameters

Based on studies that support the use of forced spirometry as a method to assess lung function in preschool children [14, 15], incentive spirometry was carried out at 4–6 years of age

FIGURE 1 | Flow chart of the study population. GA, gestational age; BPD, bronchopulmonary dysplasia.

(Jaeger®, MasterScreen®, version 5.0). Each child performed up to eight maneuvers. The following parameters were recorded for each child: force expiratory time (FET); forced vital capacity (FVC); forced expiratory volume in the first second (FEV_1) and first 0.75 s ($FEV_{0.75}$); forced expiratory flow at 75% of FVC (FEF_{75}); forced expiratory flow between 25 and 75% of FVC (FEF_{25-75}); and $FEV_1/FVC - FEV_{0.75}/FVC$. The American Thoracic Society and European Respiratory Society quality control criteria [16], modified by Stanojevic [17], were applied. Z-scores were calculated for the spirometry parameters based on Global Lung Function Initiative 2012 (GLI-2012) equations [18]. The GLI-2012 reference equations were recently validated in a cohort of healthy Spanish Caucasian preschool children aged 3–6 years [15]. The GLI-2012 software enables calculation of the percentile and z-score for each lung function parameter for each child relative to the reference population. This allowed us to determine the percentage of children who were below the lower limit of normal (LLN) for each parameter, which corresponds to 5th percentile or a z-score of −1.64.

$FEV_{0.75}$ was preferred to FEV_1 as FET can be <1 s in preschool children and $FEV_{0.75}$ is also validated to evaluate lung function.

Statistical Analysis

A sample size of 112 children was estimated to detect differences of at least 0.6 z-score points in lung function parameters between the groups with and without BPD (80% power and 95% confident interval), considering a BPD prevalence of 38% in our Neonatal Unit. The final study population with an adequate spirometric study fulfilled this condition.

Statistical analyses were performed with SPSS (version 21.0; IBM SPSS Statistics for Mac. Armonk, NY). Results are expressed as the mean (standard deviation, SD), median (interquartile range), or n (%) as appropriate. Univariate analysis was performed to assess the differences in antenatal, neonatal variables and subsequent diagnosis of recurrent wheezing during the first 4–6 years between subgroups with and without BPD. Differences were assessed using the Chi-squared or Fisher's exact test for categorical variables and the Student's t-test or Mann-Whitney U test for continuous variables. A logistic regression model was constructed, including variables for which significant results were obtained in the univariate analysis, using a backward stepwise strategy. In a second step, lung function parameters were contrasted with those of the GLI-2012 reference population [18]. Given that all lung function parameters followed a normal distribution, a one-sample t-test was used for these analyses. Lung functions parameters were compared among the different subgroups and contrasted for all antenatal, neonatal, and respiratory variables using a Student's t-test. Multivariate multiple linear regression was performed for each lung function parameter applying variables for which significant results were obtained in the univariate analysis using a backward stepwise strategy.

In all tests a $p < 0.05$ was considered statistically significant.

RESULTS

Of the 197 initially identified children, a total of 132 were eligible to participate in the study. Based on the spirometry quality

criteria applied, two acceptable spirometry curves were generated for 119 children. For each individual, the spirometric parameters of the maneuver that produced the best $FVC+FEV_1$ or $FEV_{0.75}$ values were selected. **Figure 1** shows flow chart of the study population. As indicated above, $FEV_{0.75}$ was preferred over FEV_1 since FET was <1 s in 21.21% of the eligible population. In 104 children it was possible to determine FEV_1, while in 118 $FEV_{0.75}$ was recorded.

Table 1 shows the prenatal and neonatal variables based on the development of BPD. In total, 38.6% of the population developed BPD (22% mild, 16.6% moderate-to-severe). The multivariate model revealed that GA (0.456; CI95% 0.3–0.695; $p < 0.001$), hemodynamically significant PDA (19.491; CI95% 3.765–100.91; $p < 0.001$) and late sepsis (9.906; CI95% 1.947–50.392; $p = 0.006$) were independent risk factors for the development of BPD.

No association was found between lung function parameters and family history of allergy or asthma (33.6%), atopic dermatitis (31%), and parental smoking (44.2%). A history of recurrent wheezing (48.1%) was an independent risk factor for a decrease in $FEV_{0.75}$ in the multivariate model (-0.515; CI95% -0.907 – -0.122; $p = 0.011$). Persistent recurrent wheezing at the time of the study, that can be considered as preschool asthma (16.8%), was associated with a decrease in $FEV_{0.75}$ and $FEV_{0.75}/FVC$ (obstructive pattern), however these differences were not statistically significant ($FEV_{0.75}$: -1.60 ± 1.79 SD vs. -0.96 ± 1.2 SD, $p = 0.060$; $FEV_{0.75}/FVC$: -0.9 ± 0.77 SD vs. -0.57 ± 1.05 SD, $p = 0.126$), since the study was not powered for this analysis. For the same reason, BPD did not show a significant association with either the subsequent diagnosis of recurrent wheezing or its persistence (preschool asthma) at the time of the study.

Table 2 shows lung function parameters relative to BPD diagnosis and severity. All groups showed a significant decrease in $FEV_{0.75}$, FEF_{75}, FEF_{25-75}, FEV_1/FVC and $FEV_{0.75}/FVC$ relative to the reference population, which may indicate a typical obstructive pattern. FVC was only significantly reduced in patients with a diagnosis of moderate-to-severe BPD, while FEV_1 was significantly reduced in patients with BPD of any severity, with lower values observed for moderate-to-severe BPD. **Figure 2** shows the proportion of children with $FEV_{0.75}$, FVC and $FEV_{0.75}/FVC$ below the LLN. In a significant proportion in all groups, but in particular in those with moderate-to-severe BPD, $FEV_{0.75}$ was below the LLN. Among children without BPD, 14.1% had a $FEV_{0.75}$ below the LLN. This proportion increased to 26.9% among children with mild BPD and 76.2% among those with moderate-to-severe BPD. FVC was below the LLN in a significant proportion of children only in the subgroup with moderate-to-severe BPD. The percentile distribution for the entire population and data on other parameters related to BPD diagnosis and severity are provided in the **Supplementary Material**.

As shown in **Table 3**, BPD (28 days) was associated with a significant decrease in all spirometry parameters at preschool age. When this analysis was performed for children diagnosed with BPD at 36 weeks (moderate-to-severe), the decrease in obstructive pattern parameters was more pronounced than in the total BPD group. This effect was particularly evident for $FEV_{0.75}$ (-2.63 SD) and FEF_{25-75} (-2.06 SD).

TABLE 1 | Prenatal and neonatal variables stratified according to BPD diagnosis.

	Without BPD (n = 81)	With BPD (n = 51)	p
Sex (male)	41 (50.6)	23 (45.1)	0.537
Premature rupture of membranes	32 (39.5)	21 (41.2)	0.849
Multiple gestation	37 (45.7)	28 (54.9)	0.302
Preeclampsia	12 (14.8)	4 (7.8)	0.283
Chorioamnionitis	13 (16)	15 (29.4)	0.067
Antenatal steroids	63 (77.8)	40 (78.4)	0.930
Delivery (caesarean section)	55 (67.9)	31 (60.8)	0.400
Gestational age (weeks)	30.9 ± 1.7	27.8 ± 1.7	< 0.001
Birth Weight (grams)	1,327.7 ± 222.5	995.5 ± 210.2	< 0.001
Intrauterine growth restriction	22 (27.2)	5 (9.8)	0.025
Apgar 1 min	8 (6–9)	5 (3–8)	< 0.001
Apgar 5 min	9 (9–10)	9 (7–9)	< 0.001
Intubation in delivery room	12 (14.8)	36 (70.6)	< 0.001
CRIB index	1 (0–1)	2 (1–6)	< 0.001
Surfactant administration	21 (25.9)	46 (90.2)	< 0.001
2 or more doses of surfactant	3 (3.7)	15 (29.4)	< 0.001
Early sepsis	2 (2.5)	9 (17.6)	0.003
Inotropes in the first week of life	7 (8.6)	17 (33.3)	< 0.001
Invasive ventilation	19 (23.5)	45 (88.2)	< 0.001
Invasive ventilation at day 7	7 (8.6)	26 (51)	< 0.001
High frequency oscillatory ventilation	3 (3.7)	19 (37.3)	< 0.001
Necrotizing enterocolitis	0 (0)	6 (11.8)	0.003
Hemodynamically significant PDA	4 (4.9)	32 (62.7)	< 0.001
Surgical PDA	0 (0)	13 (25.5)	< 0.001
Late sepsis	5 (6.2)	23 (45.1)	< 0.001
Hospital stay (days)	35 (28.5–45)	71 (54–87)	< 0.001

Results are expressed as frequencies for categorical variables, mean ± standard deviation for quantitative variables with normal distribution, and median (interquartile range) for variables that did not follow a normal distribution. BPD, brochopulmonary dysplasia; CRIB, clinical risk index for babies; PDA, patent ductus arteriosus.

Figure 3 shows the differences in $FEV_{0.75}$, FVC and $FEV_{0.75}/FVC$ between the different subgroups. Greater lung function impairment as evidenced by a decreased in $FEV_{0.75}$ at age 4–6 years was observed in children with mild BPD than those without, but no differences in FVC were observed between these two groups. By contrast, FVC was significantly lower in children with moderate-to-severe BPD than in those without. $FEV_{0.75}/FVC$ was significantly reduced in BPD subgroups vs. the no BPD subgroup. $FEV_{0.75}/FVC$ did not show statistically significant difference between mild and moderate-to-severe BPD.

In the multivariate model moderate-to-severe BPD was the independent risk factor most closely associated with reduced $FEV_{0.75}$ (B = -1.488, CI95% -2.077– -0.899; $p < 0.001$), followed by GA (B = 0.106, CI95% 0.010–0.202; $p = 0.031$) or recurrent wheezing (B = -0.515, CI95% -0.907– -0.122; p =

TABLE 2 | Lung function parameters in children age 4–6 years according to BPD diagnosis.

	No BPD	BPD	Mild BPD	Moderate/Severe BPD
FVC	($n = 72$)	($n = 47$)	($n = 26$)	($n = 21$)
	-0.18 ± 1.00	-0.99 ± 1.24	-0.32 ± 0.90	-1.82 ± 1.12
	(-0.42–0.05)	(-1.36– -0.63)	(-0.69–0.04)	(-2.33– -1.31)
	$p = 0.128$	$p < 0.001$	$p = 0.081$	$p = 0.020$
FEV_1	($n = 64$)	($n = 40$)	($n = 24$)	($n = 16$)
	-0.24 ± 1.03	-1.32 ± 1.02	-0.83 ± 0.82	-2.06 ± 0.84
	(-0.50–0.02)	(-1.65– -0.99)	(-1.18– -0.48)	(-2.51– -1.61)
	$p = 0.068$	$p < 0.001$	$p < 0.001$	$p < 0.001$
$FEV_{0.75}$	($n = 71$)	($n = 47$)	($n = 26$)	($n = 21$)
	-0.55 ± 1.12	-1.83 ± 1.22	-1.18 ± 0.80	-2.63 ± 1.18
	(-0.82– -0.28)	(-2.19– -1.47)	(-1.50– -0.86)	(-3.16– -2.09)
	$p < 0.001$	$p < 0.001$	$p < 0.001$	$p < 0.001$
FEF_{75}	($n = 72$)	($n = 47$)	($n = 26$)	($n = 21$)
	-0.33 ± 1.01	-1.00 ± 1.01	-0.95 ± 0.85	-1.08 ± 1.19
	(-0.57– -0.10)	(-1.30– -0.71)	(-1.29– -0.61)	(-1.63– -0.54)
	$p = 0.007$	$p < 0.001$	$p < 0.001$	$p = 0.001$
FEF_{25-75}	($n = 72$)	($n = 47$)	($n = 26$)	($n = 21$)
	-0.91 ± 0.99	-1.71 ± 0.89	-1.42 ± 0.75	-2.06 ± 0.94
	(-1.14– -0.68)	(-1.97– -1.45)	(-1.72– -1.12)	(-2.49– -1.63)
	$p < 0.001$	$p < 0.001$	$p < 0.001$	$p < 0.001$
FEV_1/FVC	($n = 64$)	($n = 40$)	($n = 24$)	($n = 16$)
	-0.44 ± 1.03	-0.86 ± 1.02	-0.92 ± 0.93	-0.78 ± 1.17
	(-0.70– -0.18)	(-1.19– -0.53)	(-1.31– -0.52)	(-1.40– -0.15)
	$p = 0.001$	$p < 0.001$	$p < 0.001$	$p = 0.018$
$FEV_{0.75}/FVC$	($n = 71$)	($n = 47$)	($n = 26$)	($n = 21$)
	-0.45 ± 1.05	-0.88 ± 0.91	-0.92 ± 0.81	-0.83 ± 1.04
	(-0.70– -0.20)	(-1.15– -0.62)	(-1.25– -0.60)	(-1.31– -0.36)
	$p = 0.001$	$P < 0.001$	$p < 0.001$	$p = 0.002$

Results are expressed as the mean ± standard deviation z-score. The 95% confidence interval and the level of significance are indicated relative to the GLI2012 reference population. BPD, bronchopulmonary dysplasia; FVC, forced vital capacity; FEV_1, forced expiratory volume in the first second; $FEV_{0.75}$, forced expiratory volume in the first 0.75 seconds; FEF_{75}, forced expiratory flow at 75% of FVC; FEF_{25-75}, forced expiratory flow between 25 and 75% of FVC.

0.011). The only independent risk factor for reduced FVC was a history of moderate-to-severe BPD (B $= -1.492$, CI95% -1.980– -1.004; $p < 0.001$).

DISCUSSION

BPD is a disease that is arbitrarily defined by its treatment rather than its pathophysiology or clinical findings (19). This fact has conditioned multiple attempts to establish the definition that best predicts the long-term respiratory outcome in this population (20). The NIH 2001 consensus definition (7) took the important step of including a BPD severity scale, in contrast to the Sheenan definition (6), and subsequent studies demonstrated that infants with severe BPD have higher rates of mortality and adverse outcomes after discharge (21). However, the definition of severe BPD was overly broad, and combined infants receiving more than 30% oxygen via low flow nasal cannula with those receiving invasive ventilation. The definition proposed by the NICHD workshop in 2018 (9) reserved grade three for infants receiving invasive ventilation or non-invasive ventilation / nasal cannula >3 l/min in addition to oxygen ≥30%. This definition also assigned a diagnosis of BDP to preterm infants who die before 36 weeks PMA due to persistent parenchymal lung disease and

respiratory failure that cannot be attributable to other neonatal morbidities. However, this definition eliminated the requirement for 28 days of oxygen therapy before 36 weeks PMA, as also occurs in Jensen's evidence-based definition (10). Indeed, the latter even eliminated from the definition the need for oxygen, which had previously formed the basis of the definition of BPD. It is very likely that the modifications introduced by the NICHD workshop and by Jensen improve the predictive capacity of the definition of BPD, although validation based exclusively on early respiratory outcome may be insufficient, and may need to also include assessment of lung function throughout childhood.

In the present study we sought to evaluate the utility of the NIH consensus definition of BPD (7) to predict lung function in preschool age children (4–6 years), as measured using forced incentive spirometry. We investigated whether basing the definition on the need for oxygen and the requirement of oxygen therapy for 28 days prior to 36 weeks PMA remain relevant to the definition of BPD.

Spirometry is one of the most commonly used techniques for evaluation of lung function, can be used in children of 3 years and older, and has been proposed as an appropriate means of assessing lung function in children and adults with a history of prematurity (22–25). However, few studies have used

FIGURE 2 | FEV0.75, FVC and FEV0.75/FVC: percentile distribution in BPD subgroups. FEV0.75 was beneath the LLN (5th percentile) in a significant proportion of children in all subgroups, as follows: no BPD, 14.1%; mild BPD, 26.9%; moderate-to-severe BPD, 76.2%. FVC was beneath the LLN in 57.1% of children in the moderate-to-severe BPD subgroup. FEV0.75/FVC was beneath the LLN in a significant proportion in BPD subgroups, as follow, no BPD, 11, 3%; mild BPD, 23, 1%; moderate-to-severe BPD, 28.6%. BPD, bronchopulmonary dysplasia; FEV0.75, forced expiratory volume in the first 0.75 s; FVC, forced vital capacity; LLN, lower limit of normal (5th percentile).

this technique in preschool age children (26). The results of a previous study (15) that analyzed the suitability of this technique for assessment of lung function in healthy preschoolers support widespread application of the GLI-2012 reference equations. The GLI-2021 group proposes using $FEV_{0.75}$ rather than FEV_1 in preschool children, as not all children of this age achieve a FET >1 second, the FEV_1/FVC ratio is very close to one, and $FEV_{0.75}$ more reliably reflects central and peripheral airway alterations. For this reason, we considered $FEV_{0.75}$ more appropriate than FEV_1 for the evaluation of lung function by forced spirometry.

Overall, our study cohort showed a significant reduction in all lung function parameters relative to GLI2012 standard values. More significant changes were observed for $FEV_{0.75}$ and FEF_{25-75}, parameters that reflect the predominance of an obstructive pattern linked to prematurity. In fact, analysis of pulmonary function parameters in the subgroup without BPD revealed significant reductions only in the parameters that reflect an obstructive pattern, in line with the findings of other studies (22, 23, 25). This alteration was considerably more significant among those with a diagnosis of BPD.

From a clinical point of view, the LLN, defined as the 5th percentile or a z-score of −1.64, is adequate when establishing normality values, even more than 80% of the predicted value

(27). In all subgroups in our cohort, values for $FEV_{0.75}$ and other obstructive pattern parameters were below the 5th percentile for a significant percentage of children. Among children without BPD or with mild BPD 14.1 and 26.9%, respectively, were below the 5th percentile for $FEV_{0.75}$. This percentage increased to 76.2% in the case of children with moderate-to-severe BPD. The percentage of children with FVC below the 5th percentile was <5% among those without BPD or with mild BPD. However, FVC was below the 5th percentile in more than 50% of those diagnosed with moderate-to-severe BPD, confirming that alteration of this parameter was exclusive to this group. The EPICure study (28) reported a similar lung function in BPD patients. In children with BPD, impairment of expiration may be due not only to airway obstruction, but also to a decrease in lung volumes. The "new BPD" corresponds to an arrest of alveolar growth, and therefore it is logical that restrictive or mixed defects in lung function will be observed. The pattern observed in children with moderate-to-severe BPD clearly differed from that seen in the other subgroups. Moreover, children with a diagnosis of mild BPD in the neonatal period presented a pattern similar to that observed in those without BPD, exhibiting no restrictive alterations but greater alterations in $FEV_{0.75}$. This greater impairment of lung function in mild BPD does not support exclusion from the

definition of BPD of the requirement of 28 days of oxygen therapy before 36 weeks PMA. Recently, Chang et al. (26)

reported a significant negative association between BPD severity and FEV_1, FVC, and FEF_{25-75}, although flow characteristics in mild BPD did not differ significantly from those of preterm children without BPD and full-term controls. It is not clear whether the more pronounced obstructive pattern observed in our cohort, characterized by a significant reduction in $FEV_{0.75}$ and $FEV_{0.75}/FVC$, will improve as these patients age. Given the absence of FVC involvement, this subgroup could be equated with that of children without BPD if improvement occurs over the following years.

Reduced small airway patency, as assessed by FEF_{25-75}, has been reported during different stages of infancy (26, 28–31). In our study, all groups showed a reduction of FEF_{25-75} relative to the reference population. However, BPD was associated with a greater alteration in small airway parameter, especially in patients with moderate-to-severe BPD.

BPD is the result of complex interactions between altered alveolar and vascular development, lesions induced by antenatal and postnatal pathogenic factors, and reparative processes in the lungs (1). In our population, GA, hemodynamically significant PDA, and late sepsis were independent risk factors for BPD. Given that some of these conditions and other antenatal and neonatal evolution variables were associated with altered lung function in the univariate analysis, we conducted a subsequent multivariate analysis, which verified that moderate-to-severe BPD is the most significant independent risk factor for lung function impairment at 4–6 years of age. BPD was the only variable associated with alterations in FVC.

Wheeze is a common diagnosis in preschool children. The prevalence presents large variations, from 7.7 to 55% in different cohorts (32). In our cohort about 50% had a history of recurrent wheezing in early childhood and in 16.8% it persisted at the time of the study. Recurrent wheezing at this age is related to viral infections and its progression to asthma is conditioned by different factors. The factors most strongly associated with progression to asthma are wheeze frequency and severity, atopy, maternal asthma severity and probably prematurity. Nevertheless, it is not clear to what extent a history of BPD involves and additional risk. Recently, the EPIPAGE cohort

TABLE 3 | Lung function parameters in children age 4–6 years according to BPD diagnosis (28 days and 36 weeks).

BPD 28 days	Without BPD	BPD	p
FVC	-0.18 ± 1.00 (n = 72)	-0.99 ± 1.25 (n = 47)	< 0.001
FEV_1	-0.24 ± 1.03 (n = 64)	-1.32 ± 1.02 (n = 40)	< 0.001
$FEV_{0.75}$	-0.55 ± 1.13 (n = 71)	-1.83 ± 1.22 (n = 47)	< 0.001
FEF_{75}	-0.33 ± 1.01 (n = 72)	-1.00 ± 1.01 (n = 47)	0.001
FEF_{25-75}	-0.91 ± 0.99 (n = 72)	-1.71 ± 0.89 (n = 47)	0.008
FEV_1/FVC	-0.44 ± 1.03 (n = 64)	-0.86 ± 1.02 (n = 40)	0.045
$FEV_{0.75}/FVC$	-0.45 ± 1.05 (n = 71)	-0.88 ± 0.91 (n = 47)	0.023
BPD 36 weeks	**Without BPD**	**BPD**	**p**
FVC	-0.22 ± 0.97 (n = 98)	-1.82 ± 1.12 (n = 21)	< 0.001
FEV1	-0.40 ± 1.01 (n = 88)	-2.06 ± 0.84 (n = 16)	< 0.001
$FEV_{0.75}$	-0.72 ± 1.08 (n = 97)	-2.63 ± 1.18 (n = 21)	< 0.001
FEF_{75}	-0.50 ± 1.00 (n = 98)	-1.08 ± 1.20 (n = 21)	0.021
FEF_{25-75}	-1.04 ± 0.95 (n = 98)	-2.06 ± 0.94 (n = 21)	< 0.001
FEV_1/FVC	-0.57 ± 1.02 (n = 88)	-0.78 ± 1.17 (n = 16)	0.467
$FEV_{0.75}/FVC$	-0.58 ± 1.01 (n = 97)	-0.83 ± 1.04 (n = 21)	0.301
	Without BPD	**Mild BPD**	**p**
FVC	-0.18 ± 1.00 (n = 72)	-0.32 ± 0.90 (n = 26)	0.534
FEV_1	-0.24 ± 1.03 (n = 64)	-0.83 ± 0.83 (n = 24)	0.013
$FEV_{0.75}$	-0.55 ± 1.13 (n = 71)	-1.18 ± 0.80 (n = 26)	0.010
FEF_{75}	-0.33 ± 1.01 (n = 72)	-0.95 ± 0.85 (n = 26)	0.007
FEF_{25-75}	-0.91 ± 0.99 (n = 72)	-1.42 ± 0.75 (n = 26)	0.018
FEV_1/FVC	-0.44 ± 1.03 (n = 64)	-0.92 ± 0.93 (n = 24)	0.052
$FEV_{0.75}/FVC$	-0.45 ± 1.05 (n = 71)	-0.92 ± 0.81 (n = 26)	0.040

Results are expressed as the mean ± standard deviation z-score. BPD, bronchopulmonary dysplasia; FVC, forced vital capacity; FEV_1, forced expiratory volume in the first second; $FEV_{0.75}$, forced expiratory volume in the first 0.75 seconds; FEF_{75}, forced expiratory flow at 75% of FVC; FEF_{25-75}, forced expiratory flow between 25 and 75% of FVC.

FIGURE 3 | $FEV_{0.75}$, FVC and $FEV_{0.75}/FVC$ in each BPD subgroup. Data are presented as the mean and standard deviation. $FEV_{0.75}$, but not FVC, was significantly reduced in the mild BPD vs. the no BPD subgroup. Both $FEV_{0.75}$ and FVC were significantly reduced in the moderate-to-severe vs. the no BPD subgroup. $FEV_{0.75}/FVC$ was significantly reduced in BPD subgroups vs. the no BPD subgroup. $FEV_{0.75}/FVC$ did not show statistically significant difference between mild and moderate-to-severe BPD. BPD, bronchopulmonary dysplasia; $FEV_{0.75}$, forced expiratory volume in the first 0.75 s; FVC, forced vital capacity.

study (33) shows that preschool wheeze and BPD were the only independent variables associated with FEV_1 impairment in adolescents, as our study shows in preschool age. Pérez Tarazona et al. (34), in a systematic review found that the prevalence of asthma was higher in children and adolescents with a history of prematurity and BPD compared with those who did not develop BPD. However, in only one of the 17 studies included, this difference reaches statistical significance.

A strength of the present study is the demonstration that incentive spirometry is adequate to analyse lung function in preschool children with a history of prematurity, in strict accordance with international quality criteria for the performance of this technique. Another strength is the multivariate analysis performed, which shows that moderate-to-severe BPD is a risk factor for lung function impairment at preschool age, independent of other neonatal variables such as gestational age, birthweight, or neonatal morbidities.

This study has several limitations. First, we applied a retrospective observational design, which is common in lung function studies in preterm newborns. Second, children with significant neurological involvement were excluded due to technical difficulties that arise when performing spirometry in these children. This decreased the sample size of the subgroup with severe BPD, which was consequently grouped with the moderate BPD subgroup for analyses. However, this is considered a minor limitation, given that most studies analyzing BPD as a primary outcome consider BPD at 36 weeks PMA.

In conclusion, the NIH consensus definition is adequately predictive of lung function measured by spirometry at 4–6 years of age. Children with a history of mild BPD present a greater degree of impairment of lung function parameters than those without, but do not present FVC reduction at the age of 4–6 years. Children with diagnosis of moderate-to-severe BPD exhibit a mixed pattern, being the only form associated with FVC impairment at this age. Future attempts to validate different BPD definitions should consider long-term respiratory outcomes. This population is at risk of not achieving full airway growth potential and developing chronic obstructive pulmonary disease in adulthood.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics and Research Committee of Aragón, CEICA (PI15/002). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

SR, CM, and CR conceived the study. SR, CM, CR, and JG-I contributed to the design of the clinical work. CR, JG-I, and CM performed the incentive spirometry studies. SR and CR were responsible for data acquisition. SR and AM performed the statistical analyses. MC and MS critically reviewed the manuscript. All authors participated in the interpretation of the study results, as well as the drafting and revision of the manuscript, and all approved the final version of the manuscript prior to submission.

FUNDING

ACKNOWLEDGMENTS

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped. 2022.830035/full#supplementary-material

REFERENCES

1. Bancalari E, Jain D. Bronchopulmonary dysplasia: 50 years after the original description. *Neonatology*. (2019) 115:384–91. doi: 10.1159/000497422

2. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. *JAMA*. (2015) 314:1039–51. doi: 10.1001/jama.2015.10244

3. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. *N Engl J Med*. (1967) 276:357–68. doi: 10.1056/NEJM196702162760701

4. Tooley WH. Epidemiology of bronchopulmonary dysplasia. *J Pediatr*. (1979) 95:851–8. doi: 10.1016/S0022-3476(79)80451-5

5. Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. *J Pediatr*. (1979) 95:819–23. doi: 10.1016/S0022-3476(79)80442-4

6. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. *Pediatrics*. (1988) 82:527–32. doi: 10.1542/peds.82.4.527

7. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med*. (2001) 163:1723–9. doi: 10.1164/ajrccm.163.7.2011060

8. Jensen EA, Wright CJ. Bronchopulmonary dysplasia: The ongoing search for one definition to rule them all. *J Pediatr*. (2018) 197:8–10. doi: 10.1016/j.jpeds.2018.02.047

9. Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, et al. Bronchopulmonary dysplasia: executive summary of a workshop. *J Pediatr*. (2018) 197:300–8. doi: 10.1016/j.jpeds.2018.01.043

10. Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. *Am J Respir Crit Care Med*. (2019) 200:751–9. doi: 10.1164/rccm.201812-2348OC

11. Ramsey PS, Lieman JM, Brumfield CG, Carlo W. Chorioamnionitis increases neonatal morbidity in pregnancies complicated by preterm premature rupture oof membranes. *Am J Obstet Gynecol.* (2005) 192:1162–6. doi: 10.1016/j.ajog.2004.11.035

12. Carrascosa-Lezcano A, Ferrández-Longás A, Yeste-Fernández D, García-Dihinx J, Romo-Montejo A, Copil A. Spanish cross-sectional growth study 2008. Part I: weight and height values in newborns of 26-42 weeks of gestational age. *An Pediatr.* (2008) 68:544–51. doi: 10.1157/13123286

13. The International Neonatal Network. The CRIB (clinical risk index for babies) score: a tool for assessing initial neonatal risk and comparing performance of neonatal intensive care units. *Lancet.* (1993) 342:193–8. doi: 10.1016/0140-6736(93)92296-6

14. Lum S. Lung function in preschool children: applications in clinical and epidemiological research. *Paediatric Respir Rev.* (2006) 7(Suppl. 1):S30–2. doi: 10.1016/j.prrv.2006.04.014

15. Martín de. Vicente C, de Mir-Messa I, Rovira-Amigo S, Torrent-Vernetta A, Gartner S, Iglesias-Serrano I, et al. Validation of global lung function initiative and all ages reference equations for forced spirometry in healthy spanish pre-schoolers. *Arch Bronconeumol.* (2018) 54:24–30. doi: 10.1016/j.arbres.2017.07.019

16. Beydon N, Davis SD, Lombardi E, Allen JL, Arets HG, Aurora P, et al. An official American Thoracic Society / European Respiratory Society statement: pulmonary function testing in preschool children. *Am J Respir Crit Care Med.* (2007) 175:1304–45. doi: 10.1164/rccm.200605-642ST

17. Stanojevic S, Wade A, Cole T, Lum S, Custovic A, Silverman M, et al. Spirometry centile charts for young caucasian children. The asthma UK collaborative Initiative. *Am J Respir Crit Care Med.* (2009) 180:547–52. doi: 10.1164/rccm.200903-0323OC

18. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J.* (2012) 40:1324–43. doi: 10.1183/09031936.00080312

19. Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, et al. Bronchopulmonary dysplasia. *Nat Rev Dis Primers.* (2019) 5:78. doi: 10.1038/s41572-019-0127-7

20. Bancalari E, Jain D. Bronchopulmonary dysplasia: can we agree on a definition? *Am J Perinatol.* (2018) 35:537–40. doi: 10.1055/s-0038-1637761

21. Ehrenkranz RA, Walsh MC, Vorh BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the national institutes of health consensus definition of bronchopulmonary dysplasia. *Pediatrics.* (2005) 116:1353–60. doi: 10.1542/peds.2005-0249

22. Choukroun ML, Feghali H, Vautrat S, Marquant F, Nacka F, Leroy V, et al. Pulmonary outcome and its correlates in school-aged children born with a gestational age (32 weeks). *Respir Med.* (2013) 107:1966–76. doi: 10.1016/j.rmed.2013.06.020

23. Lista G, Castoldi F, Bianchi S, Lupo E, Cavigioli F, Farolfi A, et al. Lung function and respiratory health at school age in ventilated very low birth weight infants. *Indian J Pediatr.* (2014) 81:275–8. doi: 10.1007/s12098-013-1129-1

24. Cardoen F, Vermeulen F, Proesmans M, Moens M, De Boeck K. Lung function evolution in children with old and new type bronchopulmonary dysplasia: a retrospective cohort analysis. *Eur J Pediatr.* (2019) 178:1859–66. doi: 10.1007/s00431-019-03453-1

25. Doyle LW, Andersson S, Bush A, Cheong JLY, Clemm H, Evensen KA, et al. Expiratory airflow in late adolescence and early adulthood in individuals born very preterm or with very low birthweight compared with controls born at term or with normal birthweight: a meta-analysis of individual participant data. *Lancet Respir Med.* (2019) 7:677–86. doi: 10.1016/S2213-2600(18)30530-7

26. Chang HY, Chang JH, Chi H, Hsu CH, Lin CY, Jim WT, et al. Reduced lung function at preschool age in survivors of very low birth weight preterm infants. *Front Pediatr.* (2020) 8:577673. doi: 10.3389/fped.2020.577673

27. Miller MR, Quanjer PH, Swanney MP, Rupple G, Enright PL. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. *Chest.* (2011) 139:52–9. doi: 10.1378/chest.10-0189

28. Fawke J, Lum S, Kirby J, Hennessy E, Marlow N, Rowell V, et al. Lung function and respiratory symptoms at 11 years in children born extremely preterm: the epicure study. *Am J Respir Crit Care Med.* (2010) 182:237–45. doi: 10.1164/rccm.200912-1806OC

29. Korhonen P, Laitinen J, Hyodynmaa E, Tammela O. Respiratory outcome in school-aged, very-low-birth-weight children in the surfactant era. *Acta Paediatr.* (2004) 93:316–21. doi: 10.1111/j.1651-2227.2004.tb02954.x

30. Simpson SJ, Turkovic L, Wilson AC, Verheggen M, Logie KM, Pillow JJ, et al. Lung function trajectories throughout childhood in survivors of very preterm birth: a longitudinal cohort study. *Lancet Child Adolesc Health.* (2018) 2:350–9. doi: 10.1016/S2352-4642(18)30064-6

31. Hacking DF, Gibson AM, Robertson C, Doyle LW, Victorian Infant Collaborative Study Group. Respiratory function at age 8-9 after extremely low birthweight or preterm birth in Victoria in 1997. *Pediatr Pulmonol.* (2013) 48:449–55. doi: 10.1002/ppul.22619

32. Bloom CI, Franklin C, Bush A, Saglani S, Quint JK. Burden of preschool wheeze and progression to asthma in the UK: Population-based cohort 2007 to 2017. *J Allergy Clin Immunol.* (2021) 147:1949–58. doi: 10.1016/j.jaci.2020.12.643

33. Hadchouel A, Rousseau J, Rozé JC, Arnaud C, Bellino A, Couderc L, et al. Association between asthma and lung function in adolescents born very preterm: results of the EPIPAGE cohort study. *Thorax.* (2018) 73:1174–6. doi: 10.1136/thoraxjnl-2017-211115

34. Pérez-Tarazona S, Solano P, Bartoll E, Alfonso J. Bronchopulmonary dysplasia as a risk factor for asthma in school children and adolescents: a systematic review. *Allergol Immunopathol.* (2018) 46:87–98. doi: 10.1016/j.aller.2017.02.004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.